Oral factor Xa inhibitors for thromboprophylaxis  in major orthopedic surgery: a review.
Venous thromboembolism (VTE), which includes deep vein thrombosis and pulmonary embolism, is a major cause of morbidity and mortality in patients undergoing major orthopedic surgery. Routine thromboprophylaxis has been the standard of care over the last 20 years. Currently available options for the prevention of VTE in major orthopedic surgery include low molecular weight heparins, vitamin K antagonists, and, more recently, the synthetic pentasaccharide fondaparinux. Although effective, all these drugs have several limitations and new oral antithrombotics offering predictable, effective and safe anticoagulation are strongly needed. This overview focuses on the most advanced oral direct inhibitors to factor Xa rivaroxaban, apixaban, LY517717 and YM150; specifically, the results of phase II and III studies and the designs of ongoing clinical trials in patients undergoing elective hip and knee replacement are reviewed.
Imberti
Davide
D
Ospedale Civile, Piacenza, Italy.
Dall'Asta
Chiara
C
Pierfranceschi
Matteo Giorgi
MG
D000284:Administration, Oral; D015951:Factor Xa / Q000008:administration & dosage*; D006801:Humans; D009985:Orthopedics; D011183:Postoperative Complications / Q000517:prevention & control; D054556:Venous Thromboembolism / Q000517:prevention & control*
D015951:Factor Xa
J Thromb Haemost. 2005 Mar;3(3):514-21
15748242
Blood. 1990 May 1;75(9):1753-62
2184900
Arterioscler Thromb Vasc Biol. 2008 Mar;28(3):380-6
18296593
J Thromb Haemost. 2007 Aug;5(8):1660-5
17663737
J Thromb Haemost. 2006 Jan;4(1):121-8
16409461
J Thromb Thrombolysis. 2006 Feb;21(1):67-72
16475045
Semin Thromb Hemost. 2006 Oct;32(7):651-8
17024592
Thromb Haemost. 2007 Oct;98(4):756-64
17938798
Chest. 2008 Jun;133(6 Suppl):381S-453S
18574271
J Thromb Haemost. 2008 May;6(5):820-9
18315548
Circulation. 2006 Nov 28;114(22):2374-81
17116766
N Engl J Med. 2008 Jun 26;358(26):2765-75
18579811
Thromb Haemost. 2008 Sep;100(3):453-61
18766262
Lancet. 2009 May 16;373(9676):1673-80
19411100
J Clin Pharmacol. 2007 Feb;47(2):218-26
17244773
N Engl J Med. 2008 Jun 26;358(26):2776-86
18579812
J Clin Pharmacol. 2006 Sep;46(9):981-90
16920892
Chest. 2008 Jun;133(6 Suppl):340S-380S
18574270
Lancet. 2008 Jul 5;372(9632):31-9
18582928
Chest. 2008 Jun;133(6 Suppl):234S-256S
18574267
Clin Orthop Relat Res. 2006 Nov;452:21-7
16906107
Thromb Res. 2007;120(5):685-93
17292948
Chest. 2004 Aug;126(2):501-8
15302737
Chest. 2004 Sep;126(3 Suppl):338S-400S
15383478
J Thromb Haemost. 2007 Dec;5(12):2368-75
17868430
Eur J Clin Pharmacol. 2005 Dec;61(12):873-80
16328318
Arch Intern Med. 1998 Mar 23;158(6):585-93
9521222
J Clin Pharmacol. 2006 May;46(5):549-58
16638738
Arterioscler Thromb Vasc Biol. 2007 Jun;27(6):1238-47
17379841
Clin Orthop Relat Res. 2005 Dec;441:56-62
16330984
J Med Chem. 2007 Nov 1;50(22):5339-56
17914785
J Thromb Haemost. 2005 Nov;3(11):2479-86
16241946
J Thromb Haemost. 2007 Apr;5(4):746-53
17408408